Mark Frost
Executive Vice President and Chief Financial Officer


Executive Vice President and Chief Financial Officer Mark Frost joined AngioDynamics in November 2012, bringing more than 25 years of global financial, administrative and operational experience, and a strong background in the healthcare industry. During his career, Mark built experience directing Corporate Development, IT, Communications, Legal and a variety of other mission critical functions, making him a well-versed leader with world-class financial and operational skills.


Mark will be one of the distinguished speakers at the 6th Semi-Annual Life Science Financial Forum.


Why are the 6th & 7th Semi-Annual Life Science Financial Forums important to financial executives?
I believe it is always important to stay current on ongoing practices and look for improved ways to operate our businesses and organizations.


What initiatives are on the horizon at your organization for the financial department in 2015-2016?
Implementing new budget/forecast cloud based solution and enhancing use of ERP capabilities to improve speed and transparency of financial/operational information.


How has your organization increased operational effectiveness within the finance department?

  • Implemented global ERP system
  • Upgraded organizational talent to match future business aspirations
  • Created business partner approach to better integrate finance/accounting teams with customers they support


How do you believe the evolving healthcare landscape has affected product pricing and value discussions?
It has driven companies to either gain scale to lower their cost base to offset price pressures on commoditized products or introduce products that are truly differentiated and demonstrate outcomes to reduce cost to the healthcare system and/or improve doctor/patient results.


What are three key areas to examine when assessing financial and operational risk?
Three key areas to assess risk would be:

  • Supply chain
  • FDA/regulatory
  • FX management


How do you see the trend of tax inversion evolving over the next several years?
It likely will slow down because of the Treasury changes and the potential that we will see real tax reform proposals.


And finally, what keeps you up at night?
Regulatory changes and FDA surprises.